34|25|Public
5000|$|... #Caption: Example of 37,500-probe DNA {{microarray}} with enlarged inset to show detail. Ayoxxa's protein <b>biochip</b> <b>technology</b> {{is developed}} {{to achieve a}} comparable multiplex protein analysis (simultaneous analysis of multiple components in a single sample) ...|$|E
50|$|But this {{collaboration}} between EIMB in Moscow and Argonne National Laboratory at Illinois {{and two other}} US-based commercial partners collapsed as result of argument on contractual arrangement between the parties in 2001. As {{a result of this}} dispute, Dr Andrei Mirzabekov resigned as a director of Argonne's <b>Biochip</b> <b>Technology</b> Centre.|$|E
50|$|A joint {{research}} project {{was announced in}} 1998 among Motorola Inc, Packard Instrument Company and the U.S. Department of Energy's Argonne National Laboratory. In 1999, the researchers at Argonne National Lab pushed the development of microarray-type <b>biochip</b> <b>technology</b> they co-designed with the Engelhardt Institute to ward off a worldwide outbreak of tuberculosis.|$|E
50|$|Optoelectronic and Piezoelectric Systems, MEMS & Nano-Systems, Optoelectronic Systems Design, Precision Metrology, Automation <b>Technology,</b> <b>Biochip</b> Systems, <b>Technology</b> Management.|$|R
40|$|Abstract: DNA {{mutation}} is {{the major}} cause of gene evolution. The variation of DNA sequence may result in genetic dis-eases, genotypes, single nucleotide polymorphism, and drug resistance of pathogens. Using <b>biochip</b> <b>technologies,</b> detec-tion of mutations can be performed in parallel under identical conditions, hereby providing a solution to continuously in-creasing demands for large-scale genetic analysis. This article reviews {{the development of the}} biochips for mutation analysis. Features, limitations and applications of various principles are discussed...|$|R
50|$|Christoph Ehlers (born 31.01.1958), is a German {{lawyer and}} entrepreneur. Ehlers is Managing Director and sole {{shareholder}} of Equicore Beteiligungs GmbH. He is co-founder of multiple technological companies (f.e. <b>Biochip</b> <b>Technologies</b> GmbH, GeneScan Europe AG, itm AG, Centogene AG but also together with Professor Lüder Gerken of Stiftung Ordnungspolitik - Centrum für Europäische Politik {{one of the}} leading German economic think tanks, and of Freiburger Vermögensmanagement GmbH, a leading German portfolio management company. He is member of various Management and Supervisory Boards, f.e. Centogene AG in Rostock.|$|R
5000|$|Turner (the only name {{by which}} he is known in the novel) is a {{mercenary}} who is employed by various corporations to help vital employees of competing corporations [...] "defect" [...] to Turner's employers. The novel begins with an account of a job in New Delhi in which Turner was nearly killed by a Slamhound, a type of mobile bomb. After three months of reconstructive surgery in Singapore, Turner takes a vacation in Mexico, where he meets and becomes sexually involved with a woman named Allison. While on the beach with Allison, Turner sees a familiar yacht close to shore and a powerboat from the yacht approaching the beach, bearing the logo of the Hosaka Corporation. Turner tells Allison to leave while he waits for the raft's passenger to come ashore. He already knows that the passenger is Conroy, another mercenary with whom Turner {{has worked in the}} past. Conroy recruits Turner for another [...] "extraction" [...] job; this time, Conroy and Turner are to help a man named Christopher Mitchell leave Maas Biolabs for Hosaka. Mitchell carries with him the expertise to design and manufacture [...] "biochips", a technology superior to the nearly ubiquitous silicon microprocessors of the era. Maas Biolabs holds the patents and secrets to <b>biochip</b> <b>technology</b> and will use every means it can to prevent Mitchell's escape. Conroy also reveals that Allison is a [...] "field psychologist" [...] working for Hosaka to monitor Turner and help his recovery.|$|E
40|$|Background: Early {{detection}} of metastases in muscle-invasive bladder cancer is crucial. Current imaging techniques provide only limited sensitivity for the {{detection of}} low volume metastases. Molecular markers and new rapid analysis techniques are therefore needed to improve metastasis detection sensitivity. High urinary matrix metalloproteinase 7 (MMP 7) levels were previously shown to be correlated with the presence of lymph node metastases. In the present study we applied a new innovative antibody-based electrical <b>biochip</b> <b>technology</b> for the quantitative detection of urinary MMP 7. Materials and methods: Preoperative urine samples were acquired from 30 bladder cancer patients (15 xN 0 and 15 xN 1 - 2) who underwent cystectomy because of muscle-invasive bladder cancer. In addition, urine samples of 15 age-matched healthy individuals were also collected. The MMP 7 analyses were performed using electrical <b>biochip</b> <b>technology</b> and a standard ELISA technique in parallel. Results: Urinary MMP 7 concentrations measured by <b>biochip</b> <b>technology</b> were significantly higher in patients with metastatic bladder cancer compared to those with organ-confined cancer. The sensitivity {{for the detection}} of lymph node metastases was over 70 % using the <b>biochip</b> <b>technology.</b> Conclusions: These results confirm MMP 7 as a promising metastasis marker in bladder cancer. The new electrical <b>biochip</b> <b>technology</b> provides a rapid and reliable quantitative method for measurement of protein markers in urine...|$|E
40|$|With {{the push}} to {{decrease}} the “cost per sample processed ” in clinical laboratories comes {{the need to develop}} improved methods for increasing sam-ple throughput. Biochips (which are used to ana-lyze thousands of clinical samples on one square centimeter silicon substrates) are expected to even-tually become the method of choice for many types of high-throughput screening applications. As <b>biochip</b> <b>technology</b> continue to find applications in clinical laboratories (1), refinements and innova-tions are occurring simultaneously that optimize the <b>biochip</b> <b>technology</b> itself for these applications. One of these innovations is Ericomp’s Novel Magnetic Labeling technology. By applying high resolution magnetic recording technology (se...|$|E
40|$|The {{appeal of}} {{microarray}} {{technology is the}} possibility of large-scale parallel determination of a variety of variables simultaneously. Hence, microarray technologies attract the interest of both the scientific and business worlds alike. High-throughput screening has been the major focus of the utilization of microarray technologies in recent years, and has provided the strong driving force for developments in this field. DNA chip and <b>biochip</b> <b>technologies</b> have been developed as a consequence of worldwide activity in genome research. This review focuses on microarray-based analysis and emphasizes some of its principal constraints, especially detection limits...|$|R
50|$|Microarrays are {{not limited}} to DNA analysis; protein microarrays, {{antibody}} microarray, chemical compound microarray can also be produced using biochips. Randox Laboratories Ltd. launched Evidence, the first protein <b>Biochip</b> Array <b>Technology</b> analyzer in 2003. In protein <b>Biochip</b> Array <b>Technology,</b> the <b>biochip</b> replaces the ELISA plate or cuvette as the reaction platform. The biochip is used to simultaneously analyze a panel of related tests in a single sample, producing a patient profile. The patient profile can be used in disease screening, diagnosis, monitoring disease progression or monitoring treatment. Performing multiple analyses simultaneously, described as multiplexing, allows a significant reduction in processing time and the amount of patient sample required. <b>Biochip</b> Array <b>Technology</b> is a novel application of a familiar methodology, using sandwich, competitive and antibody-capture immunoassays. The difference from conventional immunoassays is that, the capture ligands are covalently attached {{to the surface of the}} biochip in an ordered array rather than in solution.|$|R
50|$|Randox {{developed}} the world's first <b>biochip</b> array <b>technology</b> (BAT) in 2002. BAT is a multi-analyte testing platform which allows simultaneous quantitative or qualitative detection {{of a wide}} range of analytes from a single patient sample. It screens biological samples in a rapid, accurate and easy-to-use format.|$|R
40|$|Introduction: High {{cell density}} {{is known to}} enhance adipogenic {{differentiation}} of mesenchymal stem cells, suggesting secretion of signaling factors or cell-contact-mediated signaling. By employing microfluidic <b>biochip</b> <b>technology,</b> {{we have been able}} to separate these two processes and study the secretion pathways. Methods and results: Adipogenic differentiation of human adipose-derived stem cells (ASCs) cultured in a microfluidic system was investigated under perfusion conditions with an adipogenic medium or an adipogenic medium supplemente...|$|E
40|$|The ability {{correctly}} {{to identify}} species in a rapid and reliable manner {{is critical in}} many situations. For insects in particular, the primary tools for such identification rely on adult-stage morphological characters. For a number of reasons, however, {{there is a clear}} need for alternatives. This paper reports on {{the development of a new}} method employing DNA <b>biochip</b> <b>technology</b> for the identification of pest species within the family Tephritidae...|$|E
40|$|Diagnostic of {{pathogen}} in {{the human}} biological liquids by <b>biochip</b> <b>technology</b> is an intensively developed methodic now. The main {{and the most important}} part of biochip is the adsorbing layer. Adsorption properties of chalcogenide films to protein (rat monoclonal antibodies) were tested. The films were prepared by conventional thermal deposition technique and by pulsed laser deposition technique. Two methods were used for forming in the films the two-dimensional map of adsorbing places for probe testing. One is using photoresist properties of chalcogenide films; another is using photo-induced oxidation of chalcogenide films. It was shown Good selectivity of the developed structures to protein markers was shown...|$|E
40|$|Together with {{partners}} from the pharmaceutical and biotechnological industry, we designed production lines for manufacturing protein based arrays (e. g. Microarray Production Line® of Boehringer Mannheim) {{as well as}} production lines for manufacturing DNA based arrays, with capacities of several thousand chips per day. In our presentation, {{we focus on the}} specific requirements related to the production in a High-Troughput manner, meaning several thousand chips per day, are discussed. With the help of some examples (e. g. Microarray Production Line® of Boehringer Mannheim, "Mediaplotter" of HSG-IMIT and <b>Biochip</b> <b>Technologies)</b> we will outline some of the technical solutions meeting the specific requirements. Last, we will present a new concept to produce and process biochips. Central element of our approach is a modular production platform with standardised interfaces for energy, information and media...|$|R
40|$|Abstract—Microfluidic biochips are {{replacing}} the conventional biochemical analyzers by integrating {{all the necessary}} functions for biochemical analysis using microfluidics. Biochips are used in many application areas, such as, in vitro diagnostics, drug discovery, biotech and ecology. The focus {{of this paper is}} on continuous-flow biochips, where the basic building block is a microvalve and, by combining these microvalves, more complex units such as mixers, switches, multiplexers can be built. Al-though the complexity of biochips is increasing, they are still designed manually, using software such as AutoCAD. Another roadblock in the deployment of microfluidic biochips is the lack of test techniques: defective chips lead to repetition of experiments, which is undesirable due to increased labor and high reagent cost. This paper presents the state-of-the-art in flow-based <b>biochips</b> <b>technology</b> and emerging research challenges in the areas of physical design and testing techniques...|$|R
50|$|Geniom RT Analyzer is an {{instrument}} used in molecular biology for diagnostic testing. The Geniom RT Analyzer utilizes the dynamic nature of tissue microRNA levels as a biomarker for disease progression. The Geniom analyzer incorporates microfluidic and <b>biochip</b> microarray <b>technology</b> {{in order to}} quantify microRNAs via a Microfluidic Primer Extension Assay (MPEA) technique (figure 2).|$|R
40|$|We {{performed}} {{a screening of}} miRNAs regulated by dietary lipids in a cellular model of enterocytes, Caco- 2 cells. Our aim was to describe new lipid-modified miRNAs with an implication in lipid homeostasis and cardiovascular disease [1, 2]. For that purpose, we treated differentiated Caco- 2 cells with micelles containing the assayed lipids (cholesterol, conjugated linoleic acid and docosahexaenoic acid) and the screening of miRNAs {{was carried out by}} microarray using the μParaflo®Microfluidic <b>Biochip</b> <b>Technology</b> of LC Sciences (Huston, TX, USA). Experimental design, microarray description and raw data have been made available in the GEO database with the reference number of GSE 59153. Here we described in detail the experimental design and methods used to obtain the relative expression data...|$|E
40|$|<b>Biochip</b> <b>technology</b> has rapidly {{developed}} into a booming sec-tor in life sciences {{over the last few}} years. The several thousand articles dedicated to the topic of microarrays reflect the signifi-cance of the potential impact of this technology on the bio-sciences [1]. Most of the research has been carried out on gene expression analysis,where DNA microarrays make it possible to generate a vast amount of information from only a few experi-ments. Newly developed protein microarrays are designed for the detection, quantification and functional analysis of proteins (e. g., antibodies) [2]. Applications of protein microarrays include assessment of DNA-protein and protein-protein inter-actions. However,progress has been slow, {{in part because of the}} challenges posed by the natural differences between proteins and DNA molecules. Proteins are highly diverse conformational structures commonly consisting of twenty different amin...|$|E
40|$|With the {{completion}} of human genome project (HGP) and the international HapMap project as well as rapid development of high-throughput <b>biochip</b> <b>technology,</b> whole genomic sequencing-targeted analysis of genomic structures has been primarily finished. Application of single cell {{for the analysis of}} the whole genomics is not only economical in material collection, but more importantly, the cell will be more purified, and the laboratory results will be more accurate and reliable. Therefore, exploration and analysis of hereditary information of single tumor cells has become the dream of all researchers in the field of basic research of tumors. At present, single-cell sequencing (SCS) on malignancies has been widely used in the studies of pathogeneses of multiple malignancies, such as glioma, renal cancer and hematologic neoplasms, and in the studies of the metastatic mechanism of breast cancer by some researchers. This study mainly reviewed the SCS, the mechanisms and the methods of SCS in isolating tumor cells, and application of SCS technique in tumor-related basic research and clinical treatment...|$|E
40|$|A hydrogen-terminated Si(111) surface {{has been}} covalently {{modified}} by UV irradiation {{in the presence}} of ethyl undecylenate leading to a Si(111) -C 10 H 20 CO 2 Et surface. It is possible to carry out a diverse range of chemical manipulations of the ester group on the surface. For example, reduction with sodium borohydride provides a surface terminated with a primary alcohol. Reaction with an alkyl Grignard reagent gives a tertiary alcohol that can be acylated with acetyl chloride. Finally, hydrolysis of the ester leads to a carboxylic acid terminated surface that can be coupled to an amino acid using a standard solid phase amide coupling protocol. The surface density of the ester function can be controlled by dilution of the reacting ester with a long-chain alkene. This has the beneficial effects of minimizing the disruption of the alkyl chain packing in the monolayers and avoiding steric blocking of the ester group. It is expected that the ability to precisely control the average distance between large biomolecules on surfaces will impact on future molecular electronic, sensor, and <b>biochip</b> <b>technologies.</b> Peer reviewed: NoNRC publication: Ye...|$|R
40|$|Part 3 : Biometrics and Biometrics ApplicationsInternational audienceThis paper {{presents}} a rigorous offline double fault diagnosis {{as well as}} a detection technique for Digital Microfluidic Biochips (DMFBs). Due to the underlying mixed <b>technology</b> <b>biochips</b> exhibit unique failure mechanisms and defects. Thus, offline and online test mechanisms are required to certify the dependability of the system. In this paper, the proposed algorithm detects double faults anywhere in the chip satisfying the dynamic fluidic constraints and improves the fault diagnosis time to an extent...|$|R
40|$|We {{report on}} methods to {{fabricate}} robust micro- and nanopatterned platforms, comprising high functional group densities and quasi three-dimensional structures, for possible applications in <b>biochip</b> array <b>technologies.</b> For this purpose, amine-terminated poly(amidoamine) (PAMAM) dendrimers were immobilized via amide linkage formation on 11, 11 '-dithiobis(N-hydroxysuccinimidylundecanoate) (NHS-C 10) self-assembled monolayers (SAMs) on gold surfaces. The coupling reaction {{and the resulting}} assemblies were characterized by grazing incidence reflection Fourier transform infrared spectroscopy, contact angle measurements, X-ray photoelectron spectroscopy (XPS), and atomic force microscopy; the obtained surface coverage values were successfully fitted with a Langmuir isotherm. The fraction of unreacted peripheral primary amine groups of the surface-immobilized PAMAM dendrimers was 28 % as determined by XPS analysis of trifluoroacetic anhydride-labeled assemblies. Patterning of the PAMAM dendrimers on NHS-C 10 SAMs on the micrometer and sub- 100 -nm scale was achieved by microcontact printing and dip pen nanolithography. The resulting patterns are characterized by their high degree of order and stability of the transferred molecules due to covalent attachment...|$|R
40|$|We {{report on}} a novel {{covalent}} coupling method using electrochemical activation of hydroquinone mono-ester self-assembled monolayers. The reaction generates benzoquinone as a good leaving group, followed by nucleophilic acyl substitution with a primary amine to form an amide in high yield. The method allows the site-selective and the reaction-controlled positioning of biotin on the individually addressable microelectrode array and, subsequently, density-differentiated patterning of streptavidin on the biotin surfaces. Because the electrochemical coupling method provides a very rapid, mild, and quantitatively controllable reaction pathway for covalent bond formation on organic surfaces, {{it will be used}} as a versatile molecular anchoring tool in fields such as molecular electronics and <b>biochip</b> <b>technology.</b> Various methods to functionalize surfaces by anchoring molecules have been investigated intensively. As a result of its simplicity and diversity, the most popular scheme is covalent coupling, 1 that is, direct bond formation by the reaction of nucleophile-containing molecules with acti-vated molecular surfaces. In this paper, we {{report on a}} novel covalent coupling method using electrochemica...|$|E
40|$|Epidermolysis bullosa acquisita {{is a rare}} {{autoimmune}} bullous disease {{characterized by}} the presence of circulating antibodies directed against the collagen type VII. Diagnosis is generally based on clinical history, clinical features, histology, direct and indirect immunofluorescence, immunoblotting and ELISA. Our study aims to determine the validity of the Biochip immunofluorescence microscopy for the serological diagnosis of epidermolysis bullosa acquisita. Six patients with epidermolysis bullosa acquisita and presence of antibodies against type VII collagen confirmed by ELISA were included in the study. Subsequently, all sera of patients were analyzed using Biochip. Antibodies anti-collagen type VII were detected in all sera by means of the <b>Biochip</b> <b>technology.</b> Thus, Biochip shows a good correlation with ELISA and seems to be an appropriate method for the diagnosis of epidermolysis bullosa acquisita. It is an easy, fast and standardized method which could facilitate the diagnosis of this autoimmune bullous disease. We suggest that it could be used as an initial screening test to identify patients with epidermolysis bullosa acquisita...|$|E
30|$|In {{the sense}} of the above discussion, the {{generating}} part can also be called the transient part. In other words, the electro-osmotic flow generated by the AC electric field is quasi-periodic. In spite of this, the generating part of the solution is very important for the researcher in this field, since it explains both the characteristics of electro-osmotic flow and the practical applications due to rapid development of the <b>biochip</b> <b>technology</b> [14]. Furthermore, in a study of the stability of a colloidal system, Overbeek [15] pointed out that the relaxation time for surface charges (about 10 − 6 to 104 s) and the time scale for Brownian coagulation (about 10 − 7 to 10 − 5 s) are very different; the aggregation of colloidal particles may occur earlier than the equilibrium of the electrical conditions near a surface. In these cases, the steady-state analysis on the electrical condition near a charged surface is unrealistic, and an extension of the conventional treatment to a temporal description is inevitable, and this is the significance of the present study.|$|E
40|$|Lab-on-a-chip (Biochip) is an {{emerging}} technology which {{is changing the}} landscape of scientific research instrumentation, drug discovery and personalized medicines by integrating modern biomedical, microfluidic and microfabrication technology to generate large scale comparable data in small equipments. ZELLCHIP TECHNOLOGIES LTD (ZellChip) is committed to commercialize a proprietary platform technology based on microfluidic single-cell <b>biochips.</b> This <b>technology</b> allows for the precise cellular electrical/photometric measurement and long-term cell tracking on single suspension cells. It has great potential in in-vitro diagnostic arenas related to personalized medicine and drug discovery. It does so by effectively evaluating drug efficacy and toxicity. Since ZellChip 2 ̆ 7 s inception, the technology has been further developed {{in the areas of}} chip design, supporting equipment and biomedical applications, such as multi-drug resistance profiling. This project provides a strategic analysis for ZellChip 2 ̆ 7 s market entry into the fast growing Biochip market and to recommend an entry strategy that will maximize the likelihood of success...|$|R
40|$|With the {{integration}} of microfluidic and MEMS <b>technologies,</b> <b>biochips</b> such as the lab-on-a-chip (LOC) devices are at the brink of revolutionizing the medical disease diagnostics industries. Remarkable advancements in the biochips industry are making products resembling Star Trek. s "tricorder" and handheld medical scanners a reality. Soon, doctors can screen for cancer {{at the molecular level}} without costly and cumbersome equipments, and discuss treatment plans based on immediate lab results. This paper develops a roadmap for a hypothetical company (XI) which is seeking to be successful in this market. The roadmapping process starts with gathering data through literature research and expert opinions, and progress through defining the market/product/technology layers, linking and integrating these layers, and finally creating a labon-a-chip for disease diagnostics technology roadmap. </p...|$|R
40|$|We have {{developed}} a <b>biochip</b> platform <b>technology</b> suitable for controlled cell-free gene expression at the micrometer scale. A new hybrid molecule, “Daisy”, was designed and synthesized to form in a single step a biocompatible lithographic interface on silicon dioxide. A protocol is described for the immobilization of linear DNA molecules thousands of base pairs long on Daisy-coated surfaces with submicrometer spatial resolution and up to high densities. On-chip protein synthesis can be obtained with a dynamic range of up to four ordersof magnitude and minimal nonspecific activity. En route to on-chip artificial gene circuits, a simple two-stage gene cascade was built, in which the protein synthesized at the first location diffuses to regulate the synthesis of another protein at a second location. We demonstrate the capture of proteins from crude extract onto micrometer-scale designated traps, an important step {{for the formation of}} miniaturized self-assembled protein chips. Our biochip platform can be combined with elastomeric microfluidic devices, thereby opening possibilities for isolated and confined reaction chambersand artificial cells in which the transport of products and reagents is done by diffusion and flow. The Daisy molecule and described approach enables groups not proficient in surface chemistry to construct active biochips based on cellfree gene expression...|$|R
40|$|INTRODUCTION: High {{cell density}} {{is known to}} enhance adipogenic {{differentiation}} of mesenchymal stem cells, suggesting secretion of signaling factors or cell-contact-mediated signaling. By employing microfluidic <b>biochip</b> <b>technology,</b> {{we have been able}} to separate these two processes and study the secretion pathways. METHODS AND RESULTS: Adipogenic differentiation of human adipose-derived stem cells (ASCs) cultured in a microfluidic system was investigated under perfusion conditions with an adipogenic medium or an adipogenic medium supplemented with supernatant from differentiating ASCs (conditioned medium). Conditioned medium increased adipogenic differentiation compared to adipogenic medium with respect to accumulation of lipid-filled vacuoles and gene expression of key adipogenic markers (C/EBPα, C/EBPβ, C/EBPδ, PPARγ, LPL and adiponectin). The positive effects of conditioned medium were observed early in the differentiation process. CONCLUSIONS: Using different cell densities and microfluidic perfusion cell cultures to suppress the effects of cell-released factors, we have demonstrated the significant role played by auto- or paracrine signaling in adipocyte differentiation. The cell-released factor(s) were shown to act in the recruitment phase of the differentiation process...|$|E
40|$|In our {{approach}} to a flexible surface-chemistry for protein-immobilization we use core-shell nanoparticles as carriers for {{all different kinds of}} capture-molecules. Silica nanospheres are equipped with an organic shell using functional silanes and state-of-the-art bioconjugate chemistry to couple specific capture proteins such as antibodies, streptavidin etc. Affinity-nanoparticles applied in suspension have proven to be a very useful tool for protein-separation. We have shown that particle-bound proteins can be analysed by MALDI mass-spectrometry directly at the particlesx surface as nanoparticles do not desturb the MALDI-process. Furthermore we have demonstrated that functional nanoparticles can be deposited on activated surfaces in a micro-structured way by combination of a broad range of top-down structuring methods. Nanoparticles display a very large surface and thus layers of functional nanoparticles adsorbed to a solid substrate display an increased amount of receptor sites per area. Hence micro-structured nanoparticle layers form highly sensitive sensor surfaces for application in protein <b>biochip</b> <b>technology.</b> We will present results concerning the maintainance of protein function on nanoparticulate chip-surfaces, the dynamic range of nanoparticle-chips and chip-readout by fluorescence-detection or MALDI-mass-spectrometry...|$|E
40|$|As humans {{prepare for}} the {{exploration}} of our solar system, {{there is a growing}} need for miniaturized medical and environmental diagnostic devices for use on spacecrafts, especially during long-duration space missions where size and power requirements are critical. In recent years, the biochip (or Lab-on-a-Chip) has emerged as a technology that might be able to satisfy this need. In generic terms, a biochip is a miniaturized microfluidic device analogous to the electronic microchip that ushered in the digital age. It consists of tiny microfluidic channels, pumps and valves that transport small amounts of sample fluids to biosensors that can perform a variety of tests on those fluids in near real time. It has the obvious advantages of being small, lightweight, requiring less sample fluids and reagents and being more sensitive and efficient than larger devices currently in use. Some of the desired space-based applications would be to provide smaller, more robust devices for analyzing blood, saliva and urine and for testing water and food supplies for the presence of harmful contaminants and microorganisms. Our group has undertaken the goal of adapting as well as improving upon current <b>biochip</b> <b>technology</b> for use in long-duration microgravity environments...|$|E
40|$|Background. Obesity is a {{disorder}} {{often accompanied by}} a heightened state of systemic inflammation and immunoactivation. The present randomized crossover trial aimed to investigate the efficacy of curcumin, a bioactive polyphenol with established anti-inflammatory and immunomodulatory effects, on the serum levels of a panel of cytokines and mediators in obese individuals. Methods. Thirty obese individuals were randomized to receive curcumin at a daily dose of 1 [*]g or a matched placebo for 4 weeks. Following a 2 -week wash-out period, each group {{was assigned to the}} alternate treatment regimen for another 4 weeks. Serum samples were collected at the start and end of each study period. Serum levels of IL- 1 α, IL- 1 β, IL- 2, IL- 4, IL- 6, IL- 8, IL- 10, VEGF, IFNγ, EGF, MCP- 1, and TNFα were measured using a multiplex <b>Biochip</b> Array <b>Technology</b> based method. Results. Mean serum IL- 1 β (P= 0. 042), IL- 4 (P= 0. 008), and VEGF (P= 0. 01) were found to be significantly reduced by curcumin therapy. In contrast, no significant difference was observed in the concentrations of IL- 2, IL- 6, IL- 8, IL- 10, IFNγ, EGF, and MCP- 1. Conclusions. The findings of the present trial suggested that curcumin may exert immunomodulatory effects via altering the circulating concentrations of IL- 1 β, IL- 4, and VEGF...|$|R
40|$|DE 102006003603 A 1 UPAB: 20071011 NOVELTY - Carriers with a first {{function}} for coupling to a ligand {{and a second}} {{function for}} binding to an immobilizing surface or for crosslinking the carriers together are new. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) conjugates comprising carriers as above coupled to a ligand through the first function and bound to an immobilizing surface or crosslinked together through the second function; (2) producing crosslinked conjugates as above by coupling the carriers to a ligand and then crosslinking the carriers together. USE - The carriers are useful as carriers for ligands for analytical, especially bioanalytical, applications (claimed), especially for nucleic acid assays, protein assays, immunoassays (including enzyme-linked immunosorbent assays and radioimmunoassays), enzymatic assays, receptor binding assays, electrophoretic and chromatographic assays, colorimetric assays, microscopic and spectroscopic assays, or assays using <b>biochip</b> or microarray <b>technology</b> or beads, or for drug screening...|$|R
40|$|Abstract: cDNA Microarrays, or <b>biochips,</b> are a <b>technology</b> used {{to measure}} gene {{expression}} on a large-scale basis. One OF the critical issues of microarray experiments iithe analysis OF the produced images, which are the raw dah from which measurements need to be made. However, the first stage, i. e. spot gridding, is not performed Fully automatically in most microarray image analysis software. A novel, non-parametric gridding technique is proposed in this paper. Basically,!he vertical and horizontal image projections are processed independently. An image is formed for each projection by plotting it into a 2 D image, yielding a binary shape. Scale-space skeletonization is then performed in order to extract hierarchical representations of the signal. Using a criterion {{based on the number}} of blocks (or spots) in the microarray image, we select the scale in which the blocks(or spots) are detected. Experimental results For block segmentation, which constitutes the most difficult task in microanay gridding, are also shown 1...|$|R
